Microbot Medical (MBOT) is continuing its transition into a commercially focused company with the election of David Wilson to the Board of Directors. David is currently the CEO of InnovHeart, an Italian-based company focused on transcatheter mitral valve replacement. Wilson replaced Mr. Yossi Bornstein, a Board member since before the Company became public in 2016, whose last term as a director ended in December 2024
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT:
- Microbot Medical closes $8.6M registered direct offering
- Largest borrow rate increases among liquid names
- Microbot Medical prices 3.79M shares at $2.27 in registered direct offering
- Microbot Medical to sell 4M shares at $1.75 in registered direct offering
- Microbot Medical Advances with LIBERTY System Milestones